AstraZeneca Faces NPPA Heat Over Symbicort Pricing, Slapped Rs 60 Crore Showcause Notice
Advertisement
New Delhi: AstraZeneca Pharma India Limited has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA), which has raised a demand of Rs 60.49 crore plus interest over alleged overcharging on its asthma drug, Symbicort Turbuhaler.
In a filing dated September 12, 2025, to BSE and NSE, the company stated, “Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that AstraZeneca Pharma India Limited (‘the Company’) has received a Show Cause Notice from National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India on September 11, 2025.”
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.